Biotech Risk Assessment

Centessa Pharmaceuticals is advancing two orexin receptor agonists — ORX750 and ORX142 — into clinical development, but the program carries a catastrophic-severity risk profile that analysts and investors cannot afford to ignore. Unlike orexin antagonists, which have a proven regulatory track record, agonists represent largely uncharted pharmacological territory with potential for serious on-target adverse effects. The distinction matters enormously for valuation models built around pipeline pro